A subsequent study with volunteers who had been immunized with ETVAX 13–23 months earlier showed a significantly better rise in IgA ALS responses to the four adhesins and LT after a single dose, indicating that ETVAX induces mucosal immunological memory that can last 1–2 years (119). The gene discussed is CD79A; the disease is amyotrophic lateral sclerosis.